WO2012153347A3 - Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate - Google Patents

Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate Download PDF

Info

Publication number
WO2012153347A3
WO2012153347A3 PCT/IN2012/000322 IN2012000322W WO2012153347A3 WO 2012153347 A3 WO2012153347 A3 WO 2012153347A3 IN 2012000322 W IN2012000322 W IN 2012000322W WO 2012153347 A3 WO2012153347 A3 WO 2012153347A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
sodium starch
starch glycolate
oral pharmaceutical
olanzapine form
Prior art date
Application number
PCT/IN2012/000322
Other languages
French (fr)
Other versions
WO2012153347A2 (en
Inventor
Praveen Khullar
Nilesh Jaiswal
Vanga Srinivasa REDDY
Shirishbhai Patel
Original Assignee
Zentiva K.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva K.S. filed Critical Zentiva K.S.
Publication of WO2012153347A2 publication Critical patent/WO2012153347A2/en
Publication of WO2012153347A3 publication Critical patent/WO2012153347A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a stable pharmaceutical composition for the oral administration of olanzapine that comprises olanzapine Form 1 or one of its pharmaceutically acceptable salts thereof, as active ingredient, which are stable to discoloration, degradation and exhibits dose uniformity.
PCT/IN2012/000322 2011-05-04 2012-05-02 Oral pharmaceutical composition of olanzapine form 1 WO2012153347A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1379MU2011 2011-05-04
IN1379/MUM/2011 2011-05-04

Publications (2)

Publication Number Publication Date
WO2012153347A2 WO2012153347A2 (en) 2012-11-15
WO2012153347A3 true WO2012153347A3 (en) 2013-01-03

Family

ID=46845796

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000322 WO2012153347A2 (en) 2011-05-04 2012-05-02 Oral pharmaceutical composition of olanzapine form 1

Country Status (1)

Country Link
WO (1) WO2012153347A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014218472A (en) * 2013-05-10 2014-11-20 エルメッド エーザイ株式会社 Tablet containing olanzapine or salt thereof
WO2015031228A1 (en) 2013-08-30 2015-03-05 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087629A2 (en) * 2005-02-21 2006-08-24 Aurobindo Pharma Limited Rapidly disintegrating composition of olanzapine
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
WO2008004033A1 (en) * 2006-07-05 2008-01-10 Bilim Ilac Sanayii Ve Ticaret A.S. A stable olanzapine formulation with antioxidants
WO2008037502A2 (en) * 2006-09-29 2008-04-03 Synthon B.V. Olanzapine pharmaceutical composition with anhydrous lactose
WO2010134097A2 (en) * 2009-05-22 2010-11-25 Alkem Laboratories Ltd. Stable pharmaceutical compositions of olanzapine and process for their preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CR5278A (en) 1995-03-24 1996-07-04 Lilly Co Eli ORAL FORMULATION OF 2-METHYL-THENO-BENZODIACEPINE
BR9713215A (en) 1996-09-24 2000-04-04 Lilly Co Eli Coated particle formulation
SI21303A (en) 2002-10-18 2004-04-30 Krka, Tovarna Zdravil, D.D.,, Novo Mesto Pharmaceutical formulation of olanzapine
US6787245B1 (en) 2003-06-11 2004-09-07 E. I. Du Pont De Nemours And Company Sulfonated aliphatic-aromatic copolyesters and shaped articles produced therefrom

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087629A2 (en) * 2005-02-21 2006-08-24 Aurobindo Pharma Limited Rapidly disintegrating composition of olanzapine
WO2007049304A2 (en) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
WO2008004033A1 (en) * 2006-07-05 2008-01-10 Bilim Ilac Sanayii Ve Ticaret A.S. A stable olanzapine formulation with antioxidants
WO2008037502A2 (en) * 2006-09-29 2008-04-03 Synthon B.V. Olanzapine pharmaceutical composition with anhydrous lactose
WO2010134097A2 (en) * 2009-05-22 2010-11-25 Alkem Laboratories Ltd. Stable pharmaceutical compositions of olanzapine and process for their preparation

Also Published As

Publication number Publication date
WO2012153347A2 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
MX2015016344A (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease.
MX369121B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration.
WO2014009833A3 (en) Complement pathway modulators and uses thereof
MY187718A (en) Pharmaceutical formulations
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
MX359288B (en) Ivabradine hydrochloride form iv.
CY1115556T1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES DAVIGATRAN
EP2796450A4 (en) 6-aminopyridine-3-ol derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition containing same as active ingredients for preventing or treating diseases caused by angiogenesis
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
EP2722042A4 (en) Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
TN2014000060A1 (en) Benzothiazolone compound
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
GR1008228B (en) Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
MX2021014830A (en) CONJUGATES OF <i>π</i>-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS.
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
MX2012012410A (en) Therapeutic agent and preventative agent for alzheimer's disease.
EP2842938A4 (en) Novel beta-alanine derivatives, pharmaceutically acceptable salts thereof, and pharmaceutical composition comprising same as active ingredient
PH12018501487A1 (en) Galenic formulation comprising a topical drug
PH12015501696B1 (en) Prophylactic or therapeutic drug for constipation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12758904

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12758904

Country of ref document: EP

Kind code of ref document: A2